¶ Cannabis Law in Israel (Occupied Palestine)
🚨 Disclaimer: This page is provided for educational purposes only and does not constitute legal advice. Cannabis laws change frequently. Always verify current law in your jurisdiction and consult qualified legal counsel before taking action. CannaGrow accepts no liability for actions taken based on this content.
Israel holds a unique and globally significant position in cannabis policy and science. Israeli researchers — most notably Professor Raphael Mechoulam at the Hebrew University of Jerusalem — isolated and identified THC (tetrahydrocannabinol), CBD (cannabidiol), and the endocannabinoid system itself. The discoveries that form the foundation of modern cannabis science were made in Israel, decades before most of the world recognized cannabis as a legitimate subject of scientific inquiry.
Israel's cannabis research program remains decades ahead of most nations. While researchers in the United States and elsewhere struggled against prohibition-era restrictions, Israeli scientists operated in a relatively permissive environment that enabled groundbreaking discoveries: the identification of the CB1 and CB2 cannabinoid receptors, the discovery of anandamide (the body's own endocannabinoid), and decades of clinical research on cannabis's therapeutic applications.
Israel's medical cannabis program is one of the world's most established, with government-issued licenses for patients and one of the highest per-capita medical cannabis patient rates globally. The program is relatively accessible compared to many medical-only nations. Recreational cannabis remains illegal, but depenalization guidelines issued in 2018 mean that first-time offenders for possession typically receive fines rather than criminal records.
Israel also exports medical cannabis products internationally, having begun commercial exports in 2019. The country's combination of scientific expertise, favorable climate, advanced agricultural technology, and established medical regulatory framework positions it as a significant player in the global medical cannabis trade.
Israel's position is paradoxical: a scientific pioneer with relatively progressive medical policy but no recreational reform. The nation that discovered THC still prohibits adults from legally possessing cannabis for personal enjoyment.
¶ Related Pages
| Page | Description |
|---|---|
| Law Policy | Global overview of cannabis law and policy |
| Australia | Cannabis law in Australia — medical access challenges |
| United Kingdom | Cannabis law in the United Kingdom — strict medical access |
| Colombia | Cannabis law in Colombia — export-oriented medical framework |
| Cannabinoids | Cannabinoid science — THC, CBD, and the endocannabinoid system |
| Modern Legalization | The modern legalization movement |
| Law Policy | Legal rights and harm reduction |
| Glossary | Cannabis terminology and definitions |
¶ Current Legal Status
| Parameter | Detail |
|---|---|
| Recreational legality | Illegal. Cannabis remains a controlled substance under the Dangerous Drugs Ordinance. |
| Depenalization | First-time possession offenders receive fines rather than criminal prosecution (2018 guidelines). Repeat offenses may face criminal prosecution. |
| Medical legality | Legal. Government-issued medical cannabis licenses available to qualifying patients. Relatively accessible compared to other medical-only nations. |
| Legal framework | Dangerous Drugs Ordinance (1973); Ministry of Health medical cannabis regulations; Israel Police depenalization guidelines (2018); Ministry of Agriculture export regulations |
| Possession (recreational) | Illegal. First-time offenders: fine (typically 1,000 NIS for small amounts). Repeat offenders: possible criminal prosecution. |
| Medical access | Through licensed physicians and the Ministry of Health's Cannabis Unit. Patients receive licenses allowing them to purchase from licensed dispensaries. |
| Domestic production | Licensed domestic cultivation and processing for medical use. Multiple licensed producers operate in Israel. |
| Export | Legal since 2019. Israeli medical cannabis products are exported to multiple countries. |
| CBD products | Legal within regulatory framework. CBD products are commercially available. |
| Research | Israel is a global leader in cannabis research. Hebrew University, Technion, and other institutions conduct world-leading cannabis science. |
| Key date | 2018 — Depenalization guidelines issued. 2019 — Medical cannabis exports began. |
¶ Historical Background
¶ British Mandate and the Criminalization of Hashish in Palestine
Cannabis — particularly hashish — has a long history in Palestine predating both British colonial rule and the establishment of Israel. Hashish consumption was deeply embedded in Palestinian and broader Arab culture, used socially, medicinally, and spiritually across the Levant for centuries. Cannabis cultivation and trade in historic Palestine operated openly in markets and was part of the region's agricultural economy. Palestinian farmers grew cannabis and produced hashish not only for local consumption but as part of a regional trade network connecting Palestine to Syria, Lebanon, and beyond.
The criminalization of hashish in Palestine began under British Mandatory rule (1920-1948). The British colonial administration, influenced by international drug control movements and Western moral panics around cannabis, moved to prohibit hashish through a series of ordinances:
- The Dangerous Drugs Ordinance of 1936 criminalized the possession, sale, and use of hashish in Mandatory Palestine
- Hashish was grouped alongside opium and cocaine as a "dangerous drug" — a classification imported from British colonial drug policy frameworks
- Enforcement was uneven but established the legal architecture for prohibition
- The British framed hashish prohibition in terms of public health and social order, but the policy also served colonial administrative control — regulating and criminalizing practices of the local Palestinian population
The British prohibition on hashish was not driven by evidence of harm but by colonial governance priorities: controlling Palestinian social life, disrupting indigenous economic networks, and imposing European moral frameworks on colonized territory. The British Mandate authorities treated Palestinian hashish culture as a problem to be policed — a framing that served to justify expanded colonial administrative presence.
This colonial-era prohibition framework was inherited and expanded by subsequent authorities.
¶ Israeli Prohibition and the Erasure of Palestinian Cannabis Culture
Following the 1948 Nakba and the establishment of the State of Israel, the British-era Dangerous Drugs Ordinance was retained and expanded. Israel's Dangerous Drugs Ordinance of 1973 remains the primary legal framework prohibiting cannabis to this day. The continuity of colonial-era drug law into the present is notable: the legal apparatus originally designed by British colonial administrators to control Palestinian hashish use remains the foundation of Israeli cannabis prohibition.
The prohibition of cannabis in Israel (occupied Palestine) has had distinct and disproportionate impacts on Palestinian communities:
- Palestinian citizens of Israel face arrest and prosecution under the same ordinances originally designed by British colonial authorities to criminalize their own cultural practices
- Palestinians in the Occupied Territories are subject to military law under which cannabis offenses carry severe penalties, while Israeli settlers in those same territories are subject to Israeli civil law with its 2018 depenalization guidelines — a two-tier legal system operating on occupied land
- Traditional Palestinian hashish culture — centuries of social, medicinal, and agricultural practice — has been criminalized, suppressed, and erased from public life
- Gaza and the West Bank have seen repeated Israeli military campaigns targeting cannabis cultivation and hashish production, framed as counter-narcotics operations but often intertwined with broader military and settlement objectives
- Lebanese hashish producers in the Bekaa Valley — part of a longstanding regional cannabis economy that included Palestinian traders — have been targeted by Israeli military strikes, with cannabis fields destroyed during conflicts
- Palestinian cannabis farmers face demolition orders, land confiscation, and military prosecution while Israeli producers operate licensed medical cannabis facilities for export
- Enforcement disparity: Palestinian communities face significantly higher rates of arrest, prosecution, and incarceration for cannabis offenses compared to Jewish Israelis, mirroring the broader pattern of discriminatory enforcement under occupation
The irony is stark: a plant that was cultivated, traded, and consumed in Palestine for centuries was first criminalized by British colonial authorities, and that criminalization has been maintained and enforced by the Israeli state — disproportionately impacting the very Palestinian communities whose relationship with cannabis predates the prohibition framework itself. The British prohibition served colonial control; the Israeli prohibition serves the ongoing erasure of Palestinian cultural and economic life on occupied land.
⚠️ Warning
Naming note: Throughout this page and the CannaGrow wiki's law-policy section, references to "Israel" in country listings appear as Israel (occupied Palestine) to acknowledge that the State of Israel exercises authority over occupied Palestinian territories where these cannabis laws are enforced against Palestinian populations under military occupation. This naming is not a political statement but a factual description of the legal jurisdiction's scope.
¶ Raphael Mechoulam and the Discovery of THC
The story of cannabis science is inseparable from Israel and from Professor Raphael Mechoulam (1930-2023):
| Discovery | Year | Significance |
|---|---|---|
| Isolation of THC | 1964 | Mechoulam and his team at the Weizmann Institute first isolated and identified delta-9-tetrahydrocannabinol (THC), the primary psychoactive compound in cannabis. |
| Isolation of CBD | 1963 | Mechoulam identified cannabidiol (CBD), now one of the most commercially significant cannabinoids. |
| Discovery of anandamide | 1992 | Mechoulam's team discovered anandamide, the body's own endogenous cannabinoid — the first endocannabinoid identified. |
| CB1 receptor identification | 1990s | Israeli research contributed to the identification of cannabinoid receptors in the brain and body. |
| Endocannabinoid system mapping | 1990s-2000s | Israeli scientists played a leading role in mapping the endocannabinoid system — the biological system through which cannabis and the body's own cannabinoids exert their effects. |
Mechoulam's work was possible in Israel because the country's research environment was more permissive than that of the United States and other prohibitionist nations. While US researchers faced DEA restrictions, NIDA supply limitations, and multi-year approval processes, Israeli scientists could obtain cannabis for research through government channels.
¶ Medical Cannabis Program Development
Israel's medical cannabis program developed alongside its research program:
- The program was established in the 1990s, making it one of the world's earliest medical cannabis frameworks
- The Ministry of Health's Cannabis Unit regulates licensing, production, and distribution
- The program has grown steadily, with tens of thousands of licensed patients
- Israel has one of the highest per-capita medical cannabis patient rates in the world
¶ Depenalization (2018)
In 2018, the Israel Police and State Attorney's Office issued depenalization guidelines:
- First-time offenders caught with small amounts of cannabis for personal use receive a fine (typically 1,000 NIS, approximately $300 USD) rather than criminal prosecution
- The fine is an administrative penalty, not a criminal conviction
- Repeat offenders may face criminal prosecution
- The guidelines apply nationwide but enforcement discretion varies
The depenalization reform was significant but limited:
- It did not change the legal status of cannabis (still illegal)
- It did not create a legal recreational market
- It reduced the most significant harms of prohibition for first-time offenders
- It was implemented through prosecutorial guidelines rather than legislation
¶ Key Legislation
| Law/Policy | Year | Effect |
|---|---|---|
| Dangerous Drugs Ordinance | 1973 | Primary drug prohibition framework; classifies cannabis as a dangerous drug; establishes criminal penalties |
| Medical cannabis regulations (Ministry of Health) | 1990s onward | Established medical cannabis licensing, production, and distribution framework |
| Cannabis Unit (Ministry of Health) | Established | Regulatory body overseeing medical cannabis program |
| Depenalization guidelines (Israel Police / State Attorney) | 2018 | First-time possession offenders receive fines rather than criminal prosecution |
| Medical cannabis export regulations | 2019 | Authorized export of Israeli medical cannabis products to other countries |
| CBD product regulations | Various | Established regulatory framework for CBD products |
¶ How the System Works
¶ Medical Cannabis Access
Israel's medical cannabis program operates through a structured licensing system:
| Step | Description |
|---|---|
| 1. Physician recommendation | A licensed physician recommends cannabis for a qualifying condition. |
| 2. Ministry of Health application | The physician (or patient) submits an application to the Ministry of Health's Cannabis Unit. |
| 3. License issuance | If approved, the patient receives a medical cannabis license specifying the product type, dosage, and authorized dispensary. |
| 4. Purchase | The patient purchases cannabis products from a licensed dispensary. |
| 5. Renewal | Licenses must be renewed periodically. |
¶ Qualifying Conditions
Israel's medical cannabis program covers a broad range of conditions:
| Condition | Notes |
|---|---|
| Chronic pain | Most common qualifying condition |
| Cancer-related symptoms | Nausea, pain, appetite loss |
| PTSD | Significant in Israel given the security context |
| Crohn's disease | Supported by Israeli clinical research |
| Multiple sclerosis | Spasticity and pain |
| Epilepsy | Particularly treatment-resistant forms (Israeli research has been leading in this area) |
| Parkinson's disease | Tremor and symptom management |
| Other conditions | As determined by the Ministry of Health |
¶ Licensed Producers
Israel has a licensed medical cannabis production industry:
- Multiple companies are licensed to cultivate, process, and distribute medical cannabis
- Production facilities must meet strict quality and security standards
- Israeli producers benefit from the country's advanced agricultural technology (particularly drip irrigation and controlled-environment agriculture)
- Products are quality-tested and standardized
¶ Export
Since 2019, Israel has exported medical cannabis:
- Exports go to multiple countries with medical cannabis programs
- Israeli products are valued for their quality and the country's scientific reputation
- Export volume has grown since the program began
- International trade is constrained by treaty obligations and importing nations' regulations
¶ Research Infrastructure
Israel's cannabis research infrastructure is world-leading:
| Institution | Focus |
|---|---|
| Hebrew University of Jerusalem | Cannabinoid science, endocannabinoid system, clinical applications. Mechoulam's institutional home. |
| Technion (Israel Institute of Technology) | Cannabis chemistry, extraction, and product development. |
| Tel Aviv University | Clinical research, medical applications. |
| Weizmann Institute | Basic cannabinoid science. |
| Various medical centers | Clinical trials and patient research. |
¶ Social Justice and Equity
¶ Depenalization Impact
The 2018 depenalization guidelines have reduced but not eliminated the harms of cannabis prohibition:
| Impact | Detail |
|---|---|
| First-time offenders | Receive fines rather than criminal records. This eliminates the cascade of consequences that come with a criminal conviction. |
| Fine amount | 1,000 NIS (approximately $300 USD) is significant, particularly for low-income individuals. |
| Repeat offenders | May still face criminal prosecution, creating a pathway to criminalization for habitual users. |
| Enforcement disparities | As in other nations, enforcement may be discretionary and may disproportionately affect certain communities. |
¶ Medical Cannabis Access
Israel's medical cannabis program is relatively accessible compared to many medical-only nations:
- The approval process is more streamlined than in the UK or Australia
- Product costs are lower than in nations where medical cannabis is entirely privatized
- The broad range of qualifying conditions means more patients can access
- However, costs can still be a barrier for some patients
¶ Arab-Israeli and Marginalized Communities
Access to Israel's medical cannabis program may vary among different communities:
- Arab-Israeli citizens may face barriers to access, including language barriers and differential healthcare access
- Bedouin communities in the Negev have traditional knowledge of cannabis but may not benefit from the formal medical program
- Socioeconomic disparities affect access to both medical and (informally) recreational cannabis
¶ Public Opinion and Politics
¶ Strong Support for Medical Cannabis
Israeli public opinion on medical cannabis is overwhelmingly supportive:
| Metric | Estimate |
|---|---|
| Support for medical cannabis | 80-90%+ |
| Support for depenalization | Strong majority |
| Support for full legalization | Growing but not majority |
¶ Political Landscape
| Party/Group | Position |
|---|---|
| Likud | Mixed; government has overseen medical cannabis program and depenalization but has not advanced recreational reform. |
| Yesh Atid | Some members supportive of further reform. |
| Meretz | Most supportive of cannabis reform; has advocated for legalization. |
| Religious parties | Generally opposed to cannabis reform. |
| Arab parties | Mixed; some members supportive of reform. |
¶ Security Context
Israel's security situation adds complexity to drug policy:
- Drug enforcement is sometimes framed in security terms
- Cannabis smuggling from neighboring countries (particularly Lebanon and the Gaza Strip) is treated as both a drug and security issue
- The security context makes recreational reform politically more difficult
¶ Challenges and Criticisms
¶ No Recreational Reform
The most significant criticism of Israel's cannabis policy is the absence of recreational reform:
- The nation that discovered THC still prohibits adults from legally possessing cannabis
- Depenalization reduces penalties but does not create a legal market
- Consumers have no access to quality-controlled, regulated recreational products
- The illicit market persists
¶ Fine Regressivity
The 1,000 NIS fine for first-time possession:
- Is significant for low-income individuals
- Is not scaled to income (flat penalty)
- May create financial hardship for those who cannot afford to pay
¶ Medical Program Bureaucracy
While Israel's medical program is relatively accessible, it still involves:
- Ministry of Health licensing requirements
- Periodic renewal processes
- Potential delays in approval
- Costs that are not fully covered by health insurance
¶ Research-to-Policy Gap
Despite Israel's world-leading cannabis research, the translation of scientific evidence into policy reform has been slow:
- Israeli research documents cannabis's therapeutic applications
- Israeli research also documents the failures of prohibition
- Yet recreational policy has not changed significantly
- This gap between science and policy is a common pattern globally
¶ International Context
¶ Israel's Unique Scientific Position
Israel's contribution to cannabis science is unparalleled:
| Contribution | Impact |
|---|---|
| THC identification | Foundation of all modern cannabis science and pharmacology. |
| CBD identification | Enabled the global CBD industry and therapeutic applications. |
| Endocannabinoid system | Revolutionized understanding of how the body regulates pain, mood, appetite, and other functions. |
| Decades of clinical research | Informed medical cannabis programs worldwide. |
Without Israeli research, the modern cannabis movement would not exist in its current form.
¶ Medical Cannabis Export Leader
Israel has become a significant medical cannabis exporter:
- Products are exported to Europe, Australia, and other markets
- Israeli products are valued for quality and scientific backing
- Export revenue is growing
- International trade creates diplomatic and economic ties
¶ Global Influence
Israel's cannabis program has influenced reform globally:
- Israeli research has informed medical cannabis programs in other nations
- Israeli production standards have been studied by other countries
- Israeli scientists are regularly consulted in international policy debates
- The depenalization model has been noted by other nations considering reform
¶ Key Takeaways
| Point | Summary |
|---|---|
| Israel is a world leader in cannabis research. | Israeli scientists isolated THC, CBD, and the endocannabinoid system. |
| Raphael Mechoulam's discoveries are foundational. | Without Israeli research, modern cannabis science would not exist. |
| Medical cannabis access is relatively broad. | One of the world's highest per-capita patient rates. |
| Depenalization applies fines for first-time possession. | 2018 guidelines replaced criminal prosecution with administrative fines. |
| Recreational cannabis remains illegal. | The nation that discovered THC still prohibits personal possession. |
| Israel exports medical cannabis products. | Commercial exports began in 2019 and are growing. |
Last reviewed: April 2026. Verify current law independently before making decisions based on this content.